文献速递脊柱关节炎

放射学轴性脊柱关节炎患者夜间脊柱疼痛改善及其对长期结局的影响:艾克利单抗 COAST-V 随机试验结果

Improvement in spinal pain at night and its impact on long-term outcomes in radiographic axial spondyloarthritis: Results from Ixekizumab COAST-V randomised trial.
PubMed 文献 · Semin Arthritis Rheum · 2024-10-23

COAST-V 试验的 52 周分析评估艾克利单抗(IXE)治疗生物制剂初治放射学轴性脊柱关节炎患者夜间脊柱疼痛的改善。第 16 周时,IXE 每 4 周组、阿达木单抗每 2 周组和安慰剂组分别有 63.0%、46.7% 和 32.2% 患者达到夜间脊柱疼痛临床重要改善(CII)。第 16 周达到 CII 与第 16 周和第 52 周疾病活动度、功能和健康相关生活质量改善相关。

要点

  • 第 16 周 IXE 每 4 周组 63.0% 患者达到夜间脊柱疼痛 CII,高于安慰剂组 32.2%。
  • 第 16 周达到夜间脊柱疼痛 CII 者第 52 周疾病活动度和生活质量持续改善。
  • IXE 每 4 周组达到 CII 者中 58.8% 和 66.7% 分别在第 16 周和第 52 周达到 ASDAS <2.1。

核心结论

  • IXE 每 4 周治疗组较安慰剂组更大比例患者达到夜间脊柱疼痛快速且有临床意义的改善,并维持至第 52 周。
  • 第 16 周达到夜间脊柱疼痛 CII 与第 16 周和第 52 周疾病活动度、功能、患者报告结局和生活质量改善相关。

研究设计与样本

  • 52 周 3 期 COAST-V 试验,纳入生物制剂初治的放射学轴性脊柱关节炎患者,随机分配至 IXE 每 2 周、IXE 每 4 周、阿达木单抗每 2 周或安慰剂至第 16 周。
  • 患者按第 16 周夜间脊柱疼痛是否达到 ≥3 分改善(定义为临床重要改善 CII)分组。
  • 采用协方差分析和逻辑回归检验第 16 周 CII 与疾病活动度、疲劳、功能、工作效率和健康相关生活质量变化之间的关联。

主要发现

  • 第 16 周达到夜间脊柱疼痛 CII 的比例:IXE 每 4 周组 63.0%(n=51),阿达木单抗每 2 周组 46.7%(n=42),安慰剂组 32.2%(n=28)。
  • IXE 每 4 周组达到夜间脊柱疼痛 CII 者中,58.8% 在第 16 周达到 ASDAS <2.1,66.7% 在第 52 周达到 ASDAS <2.1。
  • IXE 每 4 周组达到夜间脊柱疼痛 CII 者中,25.5% 在第 16 周达到 ASDAS <1.3,29.4% 在第 52 周达到 ASDAS <1.3。
  • 第 16 周和第 52 周结果显示,第 16 周达到夜间脊柱疼痛 CII 的患者疾病活动度、功能和健康相关生活质量改善。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Spinal pain at night is a major contributor to the patient burden of radiographic axial spondyloarthritis (r-axSpA), resulting in substantial functional limitations and impairment of health-related quality of life (QoL). Ixekizumab (IXE), an interleukin-17A inhibitor, has shown efficacy in patients with r-axSpA. OBJECTIVE: To assess spinal pain at night improvement up to week (W) 52 in COAST-V and to determine if clinically important improvement in spinal pain at night at W16 is associated with improvement in disease activity and other patient-reported outcomes (PROs) at W16 and W52. METHODS: The 52 W phase 3 COAST-V trial investigated the efficacy of IXE in patients with r-axSpA that were naïve to biological disease-modifying anti-rheumatic drug (bDMARD). Patients were randomised to IXE every two weeks (Q2W), IXE every four weeks (Q4W), adalimumab (ADA) Q2W, or placebo up to W16. Patients were categorised as achieving or not achieving a ≥3-point improvement, considered a clinically important improvement (CII), in spinal pain at night at W16. Associations between achieving CII in spinal pain at night at W16 and change from baseline in disease activity (ASDAS, ASAS40), Fatigue severity NRS, JSEQ, WPAI and the SF-36 survey, were tested using analysis of covariance (continuous variables) and logistic regression (binary variables). RESULTS: At W16, 63.0 % (n=51), 46.7 % (n=42), and 32.2 % (n=28) of patients treated with IXE Q4W, ADA Q2W, and placebo, respectively, had reached a CII in spinal pain at night. Of those who were treated with IXE Q4W and achieved a CII in spinal pain at night at W16, 58.8 % and 66.7 % achieved an ASDAS <2.1 at W16 and W52 while 25.5 % and 29.4 % of patients also achieved ASDAS <1.3 at W16 and W52, respectively. Results at W16 and W52 show an improvement in disease activity, functioning, and health related QoL for patients who achieved a CII in spinal pain at night at W16. CONCLUSION: A larger proportion of patients treated with IXE Q4W achieved rapid and clinically meaningful improvement in spinal pain at night versus placebo, with improvements maintained up to W52. Achieving a CII in spinal pain at night at W16 was associated with improved disease activity, functioning, PROs, and QoL at W16 and W52. TRIAL REGISTRATION: ClinicalTrials.gov NCT02696785.

来源:Semin Arthritis Rheum,查看原文。版权归原作者所有。

引用

  1. Ramiro S, Lukas C, Nissen MJ, et al. Improvement in spinal pain at night and its impact on long-term outcomes in radiographic axial spondyloarthritis: Results from Ixekizumab COAST-V randomised trial. Semin Arthritis Rheum. 2024. PMID: 39509838. doi:10.1016/j.semarthrit.2024.152571

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。